Gensco Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Gensco Pharma is a private, commercial-stage biotech company specializing in innovative drug delivery systems, primarily for pain management and related conditions. Its core business revolves around its patented transdermal and topical delivery platforms, which are commercialized through a portfolio of branded prescription products like LidoDose® and ColciGel®. The company is expanding its pipeline through strategic acquisitions, most notably the global rights to RizaFilm® (rizatriptan oral film) for migraine, with a U.S. launch planned for Q4 2025. Gensco operates as a fully integrated company, handling manufacturing, marketing, and distribution, primarily through partnerships with distributors.

Pain ManagementGoutMigraineLocal Anesthesia

Technology Platform

Patented transdermal drug delivery systems and the MDose® airless, closed-system, metered-dose topical applicator. Also holds rights to oral dissolvable film (ODF) technology via acquisition.

Opportunities

The launch of RizaFilm® offers entry into the large acute migraine market with a differentiated, convenient oral film format that addresses patient needs for water-free, portable, and fast relief.

The growing demand for non-narcotic, localized pain therapies continues to drive the market for its core transdermal gel portfolio.

Risk Factors

The company faces significant commercialization risk with its key new product, RizaFilm®, entering a highly competitive generic and branded migraine market.

Pipeline concentration and dependency on a small number of commercial products, coupled with uncertain financial resources as a private company, present material risks to growth and sustainability.

Competitive Landscape

In topical pain, Gensco competes with other specialty pharma and generic topical manufacturers. For RizaFilm®, direct competitors include generic rizatriptan tablets and other branded acute migraine therapies (e.g., ubrogepant, lasmiditan, sumatriptan nasal spray). Its competitive edge lies in its proprietary delivery technologies aiming for dose precision (MDose®) and patient convenience (ODF).

More companies in Drug Delivery & Formulation →More companies in United States →